We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) ended the recent trading session at $183.86, demonstrating a -3.04% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.66%.
Shares of the pharmaceutical witnessed a gain of 6.86% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 27, 2026. The company is predicted to post an EPS of $2.52, indicating a 15.6% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $15.27 billion, indicating a 5.65% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $10.29 per share and a revenue of $63.18 billion, demonstrating changes of +12.34% and +7.56%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.33% upward. Currently, Astrazeneca is carrying a Zacks Rank of #2 (Buy).
Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.43. This valuation marks a discount compared to its industry average Forward P/E of 23.76.
It is also worth noting that AZN currently has a PEG ratio of 1.5. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.72.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 155, placing it within the bottom 37% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
Astrazeneca (AZN - Free Report) ended the recent trading session at $183.86, demonstrating a -3.04% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.66%.
Shares of the pharmaceutical witnessed a gain of 6.86% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to go public on July 27, 2026. The company is predicted to post an EPS of $2.52, indicating a 15.6% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $15.27 billion, indicating a 5.65% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $10.29 per share and a revenue of $63.18 billion, demonstrating changes of +12.34% and +7.56%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.33% upward. Currently, Astrazeneca is carrying a Zacks Rank of #2 (Buy).
Investors should also note Astrazeneca's current valuation metrics, including its Forward P/E ratio of 18.43. This valuation marks a discount compared to its industry average Forward P/E of 23.76.
It is also worth noting that AZN currently has a PEG ratio of 1.5. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.72.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 155, placing it within the bottom 37% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.